Floatz logo

Keppra

Transformed Follicular Lymphoma (TFL)

Kite, A Gilead CompanyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Transformed Follicular Lymphoma (TFL) cohort.

Asset / SponsorPhaseRating
Conjugated Pneumococcal Vaccine
H. Lee Moffitt Cancer Center and Research Institute
Phase 2CCC
tc011
TICAROS Co., Ltd.
Phase 1/2CCC
crc01
Curocell Inc.
Phase 1/2CC
Wztl002-1
Malaghan Institute of Medical Research
Phase 1CC
Fludarabine
Malaghan Institute of Medical Research
Phase 1CC

Same molecule, other indications

Keppra is also rated in:

Epilepsy, PartialDormant
A
Indicative ·
80 / 100
View asset →
Epilepsy, Tonic-clonicDormant
BBB
Indicative ·
78 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →